A total of 152 clinical isolates of Acinetobacter baumannii from 152 patients were identified by carbon source utilization tests and examined serologically. Polyclonal rabbit immune sera against A. baumannii strains were used in checkerboard tube agglutination tests, and 20 serovars were identified. One (serovar 19) cross-reacted with genospecies 3 (serovar 3), a closely related member of the genus Acinetobacter. Several outbreaks of nosocomial cross-infection caused by serovars 4 and 10 were delineated.
During the last three decades, Acinetobacter species have gained increasing nosocomial significance (1, 5, 6, 11, 14, 16, 20-22, 27, 28, 31, 33, 34) . Very recently, the taxonomy of isolates making up the genus Acinetobacter was changed extensively by Bouvet and Grimont (7, 8) . Furthermore, these investigators determined Acinetobacter baumannii (previous designation, Acinetobacter calcoaceticus subsp. anitratus) as the species that is most often responsible for nosocomial infections. There were previous attempts aimed at typing incriminated, nosocomially significant strains of Acinetobacter, including biotyping, phage typing, serotyping, and characterization of outer membrane protein or enzyme profiles (2-4, 12, 13, 17-19, 23-26, 32) . However, most of these studies have been rendered obsolete by taxonomic developments (7, 8) . The purpose of this study was to determine whether serotyping of clinical isolates of A. baumannii, also the most prevalent species at our medical center, was feasible and afforded sufficient discrimination of strains with respect to defining outbreaks of nosocomial cross-infections. MATERIALS AND METHODS Bacteria. A total of 334 clinical isolates of Acinetobacter species (1 isolate per patient) were examined. The isolates were identified presumptively with the API-20NE miniature system (API bioMérieux, Nurtingen, Federal Republic of Germany); definitive identification was done by using carbon substrate assimilation tests with strict adherence to the method of Bouvet and Grimont (7, 8 (15) . The bacteria were maintained on TSA slants at 4°C (bimonthly transfers) and also in a mixture of 1 volume of bovine serum (Behringwerke AG, Marburg, Federal Republic of Germany) with 1 volume of brain heart infusion broth (Difco) at -65°C.
Reagents. The carbon source utilization tests involved 14 substrates used at a 0.1% (wt/vol) final concentration (Sigma Chemie GmbH Deisenhofen, Federal Republic of Germany, and E. Merck AG, Darmstadt, Federal Republic of Germany); the tubes were incubated at 30°C for 6 days by the methods of Bouvet and Grimont (7, 8) . Growth at 44°C was determined in TSB. Oxidative assimilation of glucose was checked in oxidation-fermentation medium (Difco) with 1% (wt/vol) glucose.
Preparation of A. baumannii antigens. For tube agglutination tests, cells were prepared as follows. As a check for viability and purity, each strain was subcultured onto TSA with 5% (vol/vol) sheep blood and incubated at 35°C overnight. The next morning, 10 colonies of each strain were picked and transferred to 25 ml of TSB and incubated at 35°C overnight. The cultures were then boiled for 1 h. The cell suspensions were centrifuged at 2,500 x g at 20°C for 10 min. The supernatants were discarded, and the cells were suspended in 10 ml of sterile 0.145 M NaCi (TSB cells) and stored at 4°C until further use. For rabbit immunization, the strains were handled as described above, except that after the final NaCI washing step the cell sediments were suspended in 5 ml of 0.145 M NaCI (fivefold-concentrated cells).
Production of rabbit immune sera. Male and female New Zealand White rabbits (body weight, 2 kg; SAVO Medizinische Versuchstierzuchten GmbH, Kisslegg, Federal Republic of Germany) were immunized as described previously for Serratia marcescens anti-O sera (30) . The rabbits received five intravenous injections (0.1, 0.2, 0.4, 0.8, and 0.8 ml) of fivefold-concentrated cells into the marginal ear vein at 5-day intervals. At 5 to 7 days following the last intravenous injection, the animals were anesthetized with sodium hexobarbiturate (Bayer AG, Leverkusen, Federal Republic of Germany) and bled by cardiac puncture. The sera were separated and stored at -65°C.
Tube agglutination tests. Tube agglutination tests were performed as described previously for S. marcescens (30 versely, rabbit immune sera directed against the 7 serovars of genospecies 3 did not cross-react with any of the 20 A. baumannùi serovars. Therefore, serotyping of clinical isolates of A. baumannùi and genospecies 3 with various pools of rabbit immune sera, rather than growth at 44°C (7, 8) , might afford an additional marker for the differentiation of these two phenotypically closely related bacterial species.
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